5 results
8-K
EX-99.2
ANNX
Annexon Inc
20 Dec 23
Regulation FD Disclosure
5:17pm
single ascending dose (SAD) and multiple ascending dose (MAD) healthy volunteer study of ANX1502, a first-in-kind oral, selective small molecule inhibitor
8-K
ANNX
Annexon Inc
20 Dec 23
Regulation FD Disclosure
5:17pm
On December 20, 2023, the Company also reported results from the Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) healthy volunteer … -proportional PK and targeted levels of active drug were observed across both SAD and MAD cohorts of the healthy volunteer study. Single doses of 525 mg
DRS/A
ANNX
Annexon Inc
26 Feb 20
Draft registration statement (amended)
12:00am
in 2020. We anticipate data from the healthy volunteer trial in 2020 and to initiate a Phase 2 trial in the autoimmune indication in 2021.
Future ANX009
DRS/A
ANNX
Annexon Inc
6 Dec 19
Draft registration statement (amended)
12:00am
from the healthy volunteer trial in 2020 and to initiate a Phase 2 trial in the autoimmune indication in 2021.
Future ANX009 Indications
We
DRS/A
ANNX
Annexon Inc
8 Nov 19
Draft registration statement (amended)
12:00am
indication and commence a FIH clinical trial in healthy volunteers in 2020. We anticipate data from the healthy volunteer trial in 2020 and to initiate
- Prev
- 1
- Next